- Home
- QSI vs AUTL Comparison
QSI vs AUTL Comparison
Compare QSI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | AUTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | QSI | AUTL |
|---|---|---|
| Price | $1.15 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.63 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 4.8M | 2.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,177,000.00 | ★ $51,128,000.00 |
| Revenue This Year | N/A | $669.49 |
| Revenue Next Year | $159.68 | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 40.20 | ★ 406.67 |
| 52 Week Low | $0.95 | $1.11 |
| 52 Week High | $5.77 | $2.80 |
Technical Indicators
Market Signals| Indicator | QSI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 65.42 |
| Support Level | $1.07 | $1.63 |
| Resistance Level | $1.33 | $2.05 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 22.22 | 68.31 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.